Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Citi Annual Global Healthcare Conference 2025 December 2, 2025 10:30 AM ESTCompany ParticipantsIlya Yuffa - Executive VP ...
Le Lézard

Zetagen Therapeutics Closes Oversubscribed Series B1 Round on Strength of Promising Phase 2a Data and Compelling Pipeline

Zetagen Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company pioneering first-of-its-kind, intratumoral treatments for metastatic and primary breast cancer, today announced ...
TMCnet

Biotech Valuations Rise as New Clinical Platforms Show Progress

As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles (GAAP) are increasingly recognized as meaningful signals of ...

Eli Lilly: $1 Trillion Built On One Drug Segment

Eli Lilly and Company is rated Sell due to extreme dependence on GLP-1 drugs & valuation that assumes near-perfect conditions ...
Le Lézard

Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium

Eli Lilly and Company today announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking place December 9?